+

WO1995003058A1 - Derives d'amidon oxydes utilises comme agents anti-agregation, anticoagulants et anti-arythmiques - Google Patents

Derives d'amidon oxydes utilises comme agents anti-agregation, anticoagulants et anti-arythmiques Download PDF

Info

Publication number
WO1995003058A1
WO1995003058A1 PCT/BY1993/000003 BY9300003W WO9503058A1 WO 1995003058 A1 WO1995003058 A1 WO 1995003058A1 BY 9300003 W BY9300003 W BY 9300003W WO 9503058 A1 WO9503058 A1 WO 9503058A1
Authority
WO
WIPO (PCT)
Prior art keywords
ορμ
ιοο
acidified
aggregation
salt
Prior art date
Application number
PCT/BY1993/000003
Other languages
English (en)
Russian (ru)
Inventor
Georgy Ivanovich Sidorenko
Fedor Nikolaevich Kaputsky
Tatyana Lukinichna Jurkshtovich
Sergei Ivanovich Zayats
Marina Georgievna Kolyadko
Alexandra Borisovna Samal
Andrei Valerievich Gurin
Viktor Leonidovich Nedorezov
Original Assignee
Belorussky Nauchno-Issledovatelsky Institut Kardiologii
Nauchno-Issledovatelsky Institut Fiziko-Chimicheskikh Problem Belorusskogo Gosudarstvennogo Universiteta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Belorussky Nauchno-Issledovatelsky Institut Kardiologii, Nauchno-Issledovatelsky Institut Fiziko-Chimicheskikh Problem Belorusskogo Gosudarstvennogo Universiteta filed Critical Belorussky Nauchno-Issledovatelsky Institut Kardiologii
Priority to PCT/BY1993/000003 priority Critical patent/WO1995003058A1/fr
Publication of WO1995003058A1 publication Critical patent/WO1995003058A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/18—Oxidised starch
    • C08B31/185—Derivatives of oxidised starch, e.g. crosslinked oxidised starch

Definitions

  • the invention is subject to the availability of organic compounds, biological active properties, and, in particular,
  • the invention may not be used as a pharmaceutical product, but as a combined product, it is anti-aggresive, is anti-corrosive, and is non-volatile.
  • Iz ⁇ b ⁇ e ⁇ enie m ⁇ zhe ⁇ by ⁇ ⁇ a ⁇ zhe is ⁇ lz ⁇ van ⁇ for ⁇ edu ⁇ ezhdeniya ⁇ sl ⁇ zheny ⁇ sn ⁇ vvy ⁇ se ⁇ dechn ⁇ -s ⁇ sudis ⁇ y ⁇ zab ⁇ levany: ⁇ s ⁇ g ⁇ in ⁇ a ⁇ a mi ⁇ a ⁇ da, ⁇ niches ⁇ i i ⁇ emiches ⁇ y b ⁇ lezni se ⁇ dda, a ⁇ e ⁇ s ⁇ e ⁇ za magis ⁇ alsh ⁇ s ⁇ sud ⁇ v, ⁇ mb ⁇ ebi ⁇ a and ne ⁇ y ⁇ D ⁇ U ⁇ I ⁇ .
  • the use of it in the form of an agiagulative agent is limited to the risk of accidents.
  • the gas generator can interact with the membranes of the body, changing it and causing an internal release of calcium.
  • the anti-corruption effect of the unit there is no information on the anti-corruption effect of the unit.
  • the battery is selective and transmissive as well as Calcium CURRENT SERIAL CIRCUIT.
  • B ⁇ aches ⁇ ve ⁇ alshy-zashs ⁇ ' ⁇ m ⁇ g ⁇ ⁇ en ⁇ mena ve ⁇ a ⁇ amil ⁇ bladae ⁇ vaz ⁇ di ⁇ a ⁇ i ⁇ u ⁇ yu ⁇ i, an ⁇ ia ⁇ i ⁇ miches ⁇ imi sv ⁇ ys ⁇ vami and ⁇ a ⁇ zhe ⁇ m ⁇ zi ⁇ .ag ⁇ egash ⁇ ⁇ mb ⁇ tsi ⁇ v.
  • verapamip There is information about the validity of the anti-inflammatory properties of verapamip.
  • the anti-inflammatory anticoagulant is not neglected.
  • the 20 are in business from 0 to 53; the index "w" - correspondingly from 5 to 100; and the index " ⁇ " - respectively, from 0 to 34.
  • ⁇ a ⁇ ig. 1 Presents acid-rich sodium salt (sprinkling 1) and nitrous acid-rich salt (sparing 2). “And for this abscissa, the frequency of the vibrations in the dream is given, and for the abscissa, the reproach in '.;
  • test compound is not available; ⁇ iva "b” - 6 - reflects the effect on aggregation of acidified sodium salt in a dose of 2 mg / ml; the greening “c” is the same as AND 5 mg / ml; ⁇ iva "b” - ⁇ same ⁇ And up to 10 mg / ml; on ⁇ ig. Larger, worse, the effect of 5% ⁇ livelihood of salt on the aggregate induced by
  • the original source in the amount of 20 g depletes 7 ⁇ and the incidence of 2 is absent in 35 cases.
  • the acidified detergent is disposed of and discharged in the water of Bachnera, which is dried up in an air-humid environment.
  • Hazard , where f Hazard is the content of the main regulations in acidified in '/ .; ⁇ - the volume of our plant, the only one for the sale of barium acetate; ⁇ - an interest in the economy of ⁇ réelle ⁇ ; e - a hinge of an acidic;
  • the mass of Na-sali nitric acid oxidizes the method of gel-crushing. On the basis of the calibers used, they are dealt with with different molecular masses.
  • ⁇ is the molecular mass of the oxidized acid 10 of the salt
  • the longest synthesized nitric oxide oxidized salt is the small salt of the salt - a small yellow color of 0 colors.
  • the number of cartridges was usually (3-4) * 10 ⁇ cpeto / ml.
  • This ratio is at least 1.
  • Figures 2 and 3 are given aggregates. Illusory Inhibitions of Efficiency of Oxidizing Acidulum in Salami and Other Uses of Different Types of Aggregation of Pi and All Forms
  • the anti-rhythmic activity was controlled by chalcidia and 10 types of heart arrhythmia by the method of metaphysics. (1953) at ⁇ costume ⁇ (140-200 g), which were achieved before German nausea (50 mg / kg,
  • the studied compounds were administered for 3-5 days before the administration of calvide hydrochloride (200 mg / kg).
  • test compound is in possession of the opportunity to disengage the unit by means of different IDEAS.
  • P ⁇ luchenie ⁇ IZ ⁇ D ⁇ Y ⁇ ⁇ islenn ⁇ g ⁇ ⁇ a ⁇ is small in chas ⁇ n ⁇ s ⁇ i, s ⁇ ley ⁇ islenn ⁇ g ⁇ ⁇ a ⁇ mala, ⁇ v ⁇ dya ⁇ two s ⁇ adii: wa ⁇ e ⁇ v ⁇ y s ⁇ adii ⁇ luchayu ⁇ ⁇ islenny ⁇ a ⁇ mal on v ⁇ y - s ⁇ li ⁇ islenn ⁇ g ⁇ ⁇ ⁇ and ⁇ is small and ⁇ menn ⁇ : na ⁇ iev ⁇ y, li ⁇ iev ⁇ y, ⁇ aliev ⁇ y, magviev ⁇ y. - 16 -
  • ⁇ w-variant variant of the invention is that the oxidation of sodium salt produces the oxidation of the original quantity in the amount of 20 g /. There is a quick ⁇ ⁇ ⁇ ⁇ for four hours at a constant angle of 24 hours and at a room temperature. Acidified and washed off the distilled water and filtered on the outside of the United Kingdom, dried out of the humidified atmosphere.
  • the mass of acidified ka-khala feeds the salt and separates the gel-method of large-scale decontaminated masses.
  • ⁇ , 162 where ⁇ is the molecular mass of the oxidized sugar of Sal-A;
  • the current type of synthesized compound is the small-sized, yellow-brown two-piece.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des dérivés d'amidon oxydés biologiquement actifs de la formule générale (I), dans laquelle R représente Na, K, Li, MgOH; k + m + n = 10 à 100; k = 0 à 53; m = 5 à 100; n = 0 à 34. Ces composés peuvent être utilisés pharmaceutiquement, produisant un effet combiné anti-agrégation, anti-coagulant et anti-arythmique, lequel peut être utilisé pour empêcher et traiter un infarctus du myocarde, des cardiopathies ischémiques chroniques, l'athérosclérose dans les vaisseaux sanguins principaux, la thrombophlébite ainsi que d'autres maladies.
PCT/BY1993/000003 1993-07-21 1993-07-21 Derives d'amidon oxydes utilises comme agents anti-agregation, anticoagulants et anti-arythmiques WO1995003058A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/BY1993/000003 WO1995003058A1 (fr) 1993-07-21 1993-07-21 Derives d'amidon oxydes utilises comme agents anti-agregation, anticoagulants et anti-arythmiques

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/BY1993/000003 WO1995003058A1 (fr) 1993-07-21 1993-07-21 Derives d'amidon oxydes utilises comme agents anti-agregation, anticoagulants et anti-arythmiques

Publications (1)

Publication Number Publication Date
WO1995003058A1 true WO1995003058A1 (fr) 1995-02-02

Family

ID=4083760

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BY1993/000003 WO1995003058A1 (fr) 1993-07-21 1993-07-21 Derives d'amidon oxydes utilises comme agents anti-agregation, anticoagulants et anti-arythmiques

Country Status (1)

Country Link
WO (1) WO1995003058A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006282926A (ja) * 2005-04-04 2006-10-19 Toppan Printing Co Ltd 水溶性ポリウロン酸およびその製造方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0045338A1 (fr) * 1980-08-05 1982-02-10 LABORATOIRES DEBAT Société anonyme dite: Utilisation des glycosylglucanes en gastroentérologie dans le traitement des colopathies
US4507286A (en) * 1982-03-22 1985-03-26 Rorer Italiana, S.P.A. Polysaccharide having antiinflammatory and platelet antiaggregation activity
WO1990012579A1 (fr) * 1989-04-20 1990-11-01 Louis George Lange, Iii Utilisation de polysaccharides sulfates synthetiques non absorbables pour diminuer l'absorption de cholesterol

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0045338A1 (fr) * 1980-08-05 1982-02-10 LABORATOIRES DEBAT Société anonyme dite: Utilisation des glycosylglucanes en gastroentérologie dans le traitement des colopathies
US4396611A (en) * 1980-08-05 1983-08-02 Laboratoires Debat Glycosylglucans and application in gastroenterology
US4507286A (en) * 1982-03-22 1985-03-26 Rorer Italiana, S.P.A. Polysaccharide having antiinflammatory and platelet antiaggregation activity
WO1990012579A1 (fr) * 1989-04-20 1990-11-01 Louis George Lange, Iii Utilisation de polysaccharides sulfates synthetiques non absorbables pour diminuer l'absorption de cholesterol

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006282926A (ja) * 2005-04-04 2006-10-19 Toppan Printing Co Ltd 水溶性ポリウロン酸およびその製造方法

Similar Documents

Publication Publication Date Title
DE602004008927T2 (de) Verwendung von nitritsalzen zur behandlung von kardiovaskulären erkrankungen
JPS5838421B2 (ja) 分岐鎖状ケト酸のオルニチン及びアルギニン塩並びに肝臓及び腎臓障害の治療への使用
Kehoe Tetra-ethyl lead poisoning: clinical analysis of a series of nonfatal cases
EP1172373B1 (fr) Procédé de preparation d'oligopeptides de zinc qui sont resorbés facilement par le corps humain
JPH02191217A (ja) イノシトールトリホスフェートを含有する組織の損傷に対する医薬
DK174978B1 (da) Anvendelse af human koagulationsfaktor XIII til fremstilling af et lægemiddel til hindring af intraventrikulær blødning hos for tidligt fødte børn
RU2137472C1 (ru) Лекарственный препарат "гистохром" для лечения острого инфаркта миокарда и ишемической болезни сердца
WO1995003058A1 (fr) Derives d'amidon oxydes utilises comme agents anti-agregation, anticoagulants et anti-arythmiques
Munk et al. Pheochromocytoma presenting with pulmonary edema and hyperamylasemia
Berry et al. Aluminium phosphide: toxicity mechanism and credible treatments
RU2178296C1 (ru) Инфузионный раствор для лечения заболеваний сердечно-сосудистой системы
Lee et al. Severe glyphosate-surfactant intoxication: successful treatment with continuous renal replacement therapy
CARNRICK et al. Methemoglobinemia: Treatment with ascorbic acid
RU2242236C1 (ru) Способ инфузионной терапии при кетоацидотической коме у больных с сахарным диабетом
Closs et al. Methanol poisoning
RU2180236C2 (ru) Способ лечения ожогового шока
Külbay et al. A case of accidental benzalkonium chloride (10%) ingestion
RU2155583C2 (ru) Способ лечения отравлений, вызванных фосфорорганическими веществами
US4421743A (en) Antihypertension treatment
Green Oxygenation therapy unproven treatments for cancer and AIDS
Lee et al. Continuous Renal Replacement Therapy in a Patient with Cardiac Arrest after Glyphosate‐Surfactant Herbicide Poisoning
RU2163125C2 (ru) Способ лечения острого ишемического инсульта
CN111372573B (zh) 多离子输注溶液
RU2109512C1 (ru) Средство нормализации системы перекисного окисления липидов мозга
RU2353378C1 (ru) Способ лечения и профилактики сердечно-сосудистых заболеваний с использованием экстракта травы первоцвета весеннего

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): DE FI GB HU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载